Predictors and rates of adverse events (AEs) among non-metastatic prostate cancer (nmPC) patients (pts) treated with bicalutamide, abiraterone, or enzalutamide following surgical/medical castration.

Anuj Shah,Arif Hussain,Ruchit Shah,Shelly Ikeme,Ateesha F. Mohamed,Marc F. Botteman,Reg Waldeck

Predictors and rates of adverse events (AEs) among non-metastatic prostate cancer (nmPC) patients (pts) treated with bicalutamide, abiraterone, or enzalutamide following surgical/medical castration.

2019

Anuj Shah
Arif Hussain
Ruchit Shah
Shelly Ikeme
Ateesha F. Mohamed
Marc F. Botteman
Reg Waldeck

e16556Background: The castration-resistant nmPC treatment landscape has evolved following the recent approval of enzalutamide and abiraterone. Skin rash, fractures, and central nervous system (CNS)...

Keywords:

Castration
Prostate cancer
Pathology
Abiraterone
Oncology
Internal medicine
Adverse effect
Enzalutamide
Bicalutamide
Medicine
Rash
non metastatic

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations